Breaking News

You are here » Indian-Commodity  :  Commodities  :  Gold, Silver & Bullion  :  Gold futures end tad higher on Wednesday

03-May2018

Gold futures end tad higher on Wednesday

Gold futures ended marginally higher on  Wednesday, as dollar weakened after the U.S. Federal Reserve's dovish remarks. However, bullion remained vulnerable to a weak investment demand.

Gold futures for June delivery settled down $1.20, or 0.1 percent, at $1,305.60 per ounce, on the Comex division of the New York Mercantile. While, spot gold was up by 0.7 percent at $1,312.14 per ounce.



Related News

View all news

Gold futures end lower ahead of Fed meet

Gold futures ended lower on Thursday due to cautious outlook ahead to the Federal Reserve meeting that is expected to come up with higher rates next week. Meanwhile, positive trend in dollar index and......

Gold futures trade higher on MCX

Gold futures traded higher on MCX as traders enlarged their holdings amid a firming global trend as the dollar weakened on receding fears of a full-blown Sino-United States trade war. Investors are awaiting......

Gold futures settle higher on Wednesday

Gold futures settled higher on Wednesday, due to easing dollar index amid latest round of tariffs by China and the United States. However, the 'modest risk aversion' attitude in the world marketplace capped......

Top News

View all news

Tijaria Polypipes bags order worth Rs 35.30 crore

Tijaria Polypipes has received a single order of Rs 35.30 crore for supply of HDPE & PLB Ducts from Tata Projects. The same has to be executed within a period of 3 months. The company takes great......

RIL's telecom arm enters into 5 year partnership with Star India

Reliance Industries' (RIL) telecom arm -- Reliance Jio Infocomm (Jio) -- has entered into 5 year partnership with India's leading broadcaster, Star India to unleash a new era in sports entertainment. Jio......

Sun Pharma receives Australian TGA approval for ILUMYA

Sun Pharmaceutical Industries has received the Australian Therapeutic Goods Administration (TGA) approval for its specialty product, ILUMYA (tildrakizumab) for the treatment of adults with moderate-to-severe......